Leflunomide-induced acute hepatitis.

Article Details

Citation

Copy to clipboard

Sevilla-Mantilla C, Ortega L, Agundez JA, Fernandez-Gutierrez B, Ladero JM, Diaz-Rubio M

Leflunomide-induced acute hepatitis.

Dig Liver Dis. 2004 Jan;36(1):82-4.

PubMed ID

14971821 [ View in PubMed

]

Abstract

Leflunomide, a new immunomodulatory agent, was prescribed to a 67-year-old female patient with rheumatoid arthritis. Fifteen days later she developed diarrhoea and elevated liver enzymes. A liver biopsy showed a pattern of acute hepatitis. The patient was homozygous for the rare CYP2C9*3 allele, which determines the slowest metabolic rate for CYP2C9 enzymatic activity, that is probably involved in the metabolism of leflunomide. Liver damage subsided in few weeks. This case illustrates the risk of hepatotoxicity by leflunomide and suggests that it is possibly related to CYP2C9 polymorphism.

DrugBank Data that Cites this Article

Drug Enzymes

Drug	Enzyme	Kind	Organism	Pharmacological Action	Actions
Leflunomide	Cytochrome P450 2C9	Protein	Humans	Unknown	Substrate Inhibitor	Details

Drug Interactions

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drugs	Interaction
Integrate drug-drug interactions in your software
Leflunomide Naltrexone	The risk or severity of liver damage can be increased when Naltrexone is combined with Leflunomide.
Leflunomide Isoniazid	The risk or severity of liver damage can be increased when Isoniazid is combined with Leflunomide.
Leflunomide Regorafenib	The risk or severity of liver damage can be increased when Regorafenib is combined with Leflunomide.
Leflunomide Bosentan	The risk or severity of liver damage can be increased when Bosentan is combined with Leflunomide.
Leflunomide Nevirapine	The risk or severity of liver damage can be increased when Nevirapine is combined with Leflunomide.